Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Lmcg Investments LLC Acquires 96,793 Shares of Baxter International Inc. $BAX

Baxter International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Lmcg Investments LLC acquired 96,793 shares of Baxter International during the third quarter, valued at approximately $2.3 million. Institutional investors collectively own 90.19% of the company.
  • Baxter reported quarterly revenue of $2.96 billion and adjusted earnings of $0.56 per share, beating analyst estimates, while revenue increased 5.3% year over year. The company maintained fiscal 2026 EPS guidance of $1.95 to $2.15.
  • Analyst sentiment remains cautious: the stock has an average “Reduce” rating and a $21.73 price target, below its reported share price of $24.74. Baxter also pays a quarterly dividend of $0.01, representing a 0.2% yield.
  • Want to know the moment analysts change their view on Baxter International? Get MarketBeat All Access for $149 a year and keep that rate for life.

Lmcg Investments LLC acquired a new stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 96,793 shares of the medical instruments supplier's stock, valued at approximately $2,323,000.

A number of other institutional investors have also recently made changes to their positions in BAX. BlackRock Inc. acquired a new position in Baxter International during the 2nd quarter valued at about $1,744,874,000. Pzena Investment Management LLC purchased a new stake in Baxter International in the second quarter valued at about $1,392,098,000. Equity Investment Corp purchased a new stake in Baxter International in the second quarter valued at about $146,815,000. Bank of America Corp DE acquired a new stake in Baxter International in the second quarter worth about $132,993,000. Finally, Bank of New York Mellon Corp acquired a new stake in Baxter International in the second quarter worth about $68,036,000. Institutional investors and hedge funds own 90.19% of the company's stock.

Baxter International Price Performance

Shares of BAX opened at $24.74 on Thursday. The firm has a market capitalization of $12.79 billion, a PE ratio of -11.95, a price-to-earnings-growth ratio of 3.71 and a beta of 0.65. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The company's fifty day moving average price is $24.81 and its 200-day moving average price is $22.06. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $30.00.

Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. The company had revenue of $2.96 billion during the quarter, compared to analysts' expectations of $2.80 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. The firm's revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, equities research analysts predict that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Stockholders of record on Friday, August 28th were paid a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date was Friday, August 28th. Baxter International's dividend payout ratio (DPR) is presently -1.93%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BAX. Wolfe Research began coverage on Baxter International in a research note on Tuesday. They set a "peer perform" rating on the stock. Barclays initiated coverage on shares of Baxter International in a report on Wednesday, October 7th. They set an "underweight" rating and a $20.00 price objective on the stock. Citigroup decreased their price objective on shares of Baxter International from $28.00 to $27.00 and set a "neutral" rating for the company in a research report on Monday, October 5th. TD Cowen lifted their target price on shares of Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a research note on Monday, July 27th. Finally, Wall Street Zen cut shares of Baxter International from a "buy" rating to a "hold" rating in a research note on Saturday, October 10th. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $21.73.

View Our Latest Analysis on BAX

Baxter International Profile

(Free Report)

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter's portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.

See Also

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Baxter International Right Now?

Before you consider Baxter International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.

While Baxter International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines